TOBI PODHALER (TOBRAMYCIN)
- Respiratory cystic fibrosis p. aeruginosa colonization
- Synergy for p. aeruginosa infection in cystic fibrosis
28 mg capsules for inhalation
- Inhale the contents of 4 capsules (112 mg) by inhalation route every 12 hours for 28 days
28 mg capsule with inhalation device
- Inhale the contents of 4 capsules (112 mg) by inhalation route every 12 hours for 28 days
Respiratory cystic fibrosis p. aeruginosa colonization
- Inhale the contents of 4 capsules (112 mg) by inhalation route every 12 hours for 28 days
Synergy for p. aeruginosa infection in cystic fibrosis
- Inhale the contents of 4 capsules (112 mg) by inhalation route every 12 hours for 28 days
- Vivotif Berna Vaccine
- typhoid vaccine
Contraindicated
- Zemuron
- Xeomin
- vecuronium bromide
- Terrell
- succinylcholine chloride
- rocuronium
- rimabotulinumtoxinB
- Quelicin
- pancuronium
- onabotulinumtoxinA
- Nimbex
- Myobloc
- isoflurane
- incobotulinumtoxinA
- Forane
- enflurane
- Dysport
- Compound 347
- cisatracurium
- Botox Cosmetic
- Botox
- atracurium
- Anectine
- abobotulinumtoxinA
Severe
Moderate
- Zosyn In Dextrose (iso-osm)
- Zosyn
- Zinacef In Sterile Water
- Zinacef
- Unasyn
- Timentin
- ticarcillin-clavulanate
- Tazicef
- Sodium Edecrin
- Rocephin
- piperacillin-tazobactam-dextrs
- piperacillin-tazobactam
- Pfizerpen-g
- penicillin G sodium
- penicillin G procaine
- penicillin G potassium
- penicillin G pot in dextrose
- penicillin G benzathine & proc
- penicillin G benzathine
- oxacillin in dextrose(iso-osm)
- oxacillin
- Osmitrol 5 %
- Osmitrol 20 %
- Osmitrol 15 %
- Osmitrol 10 %
- nafcillin in dextrose iso-osm
- nafcillin
- Mefoxin In Dextrose (iso-osm)
- Maxipime
- mannitol 5 %
- mannitol 25 %
- mannitol 20 %
- mannitol 15 %
- mannitol 10 %
- Lasix
- Keflex
- furosemide
- Fortaz In Dextrose 5 %
- Fortaz
- ethacrynate sodium
- Claforan
- cephalexin
- cefuroxime-dextrose (iso-osm)
- cefuroxime sodium
- cefuroxime in sterile water
- cefuroxime axetil
- ceftriaxone in dextrose,iso-os
- ceftriaxone
- Ceftin
- ceftibuten
- ceftazidime-dextrose (iso-osm)
- ceftazidime in D5W
- ceftazidime
- cefprozil
- cefpodoxime
- cefoxitin in dextrose, iso-osm
- cefoxitin in dextrose 3.9 %
- cefoxitin
- cefotetan in dextrose, iso-osm
- cefotetan
- cefotaxime
- cefepime in dextrose,iso-osm
- cefepime in dextrose 5 %
- cefepime
- cefdinir
- cefazolin in dextrose (iso-os)
- cefazolin
- cefadroxil
- cefaclor
- Cedax
- Bicillin L-a
- Bicillin C-r
- ampicillin-sulbactam
- ampicillin sodium
- None
Contraindicated
- Disorder of the 8th cranial nerve
- Kidney disease with reduction in GFR
- Myasthenia gravis
- Parkinsonism
- Tinnitus
- Vertigo
Severe
Moderate
- Asthma
- Chronic obstructive pulmonary disease
TOBI PODHALER (TOBRAMYCIN)
- Respiratory cystic fibrosis p. aeruginosa colonization
- Synergy for p. aeruginosa infection in cystic fibrosis
- None
- Cough
- Diarrhea
- Dyspnea
- Fever
- Headache disorder
- Hemoptysis
- Voice change
More Frequent
Severe
Less Severe
- None
- Dysgeusia
- Laryngitis
- Myalgias
- Nausea
- Non-cardiac chest pain
- Pharyngitis
- Tinnitus
- Vomiting
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Aphonia
- Auditory neurotoxicity
- Bronchospastic pulmonary disease
- Nephrotoxicity
- Neuromuscular blockade
- Ototoxicity
Less Severe
- Anorexia
- Ataxia
- Dizziness
- Pain in oropharynx
- Pruritus of skin
- Skin rash
- Urticaria
- Vertigo
- Wheezing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Tobramycin (Inhal)
Safety and efficacy under the age of 6 years not established.
- 1 Day – 6 Years
- Safety and efficacy under the age of 6 years not established.
Tobramycin (inh)
- Severity Level:
2
- Additional Notes: Systemic absorption is likely low after oral inhalation
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Tobramycin
Poor oral absorption; unlikely clinically significant levels in infant
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Poor oral absorption; unlikely clinically significant levels in infant |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Tobramycin (inhalation)
Renal- Monitor renal function with known or suspected renal dysfunction. Neuro/Psych- Use with caution with underlying neuromuscular disorder. Test hearing if at risk for ototoxicity or with anticipated prolonged therapy.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
Respiratory cystic fibrosis p. aeruginosa colonization | |
B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
E84.0 | Cystic fibrosis with pulmonary manifestations |
Synergy for p. aeruginosa infection in cystic fibrosis | |
B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
E84.0 | Cystic fibrosis with pulmonary manifestations |
0-9 | A-Z |
---|---|
B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
E84.0 | Cystic fibrosis with pulmonary manifestations |
E84.0 | Cystic fibrosis with pulmonary manifestations |